Preimplantation Genetic Testing Market by Product & Service (Reagents, Consumables, Instruments, Software), Technology (NGS, PCR, SNP, CGH), Procedure (Screening, Diagnosis), Application (Aneuploidy, HLA Typing), Type of cycle - Global Forecast to 2030

icon1
USD 636.4 MN
MARKET SIZE, 2030
icon2
CAGR 10.5%
(2025-2030)
icon3
300
REPORT PAGES
icon4
200
MARKET TABLES

OVERVIEW

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The preimplantation genetic testing market is projected to reach USD 1,135.0 million by 2030 from USD 690.2 million in 2025, at a CAGR of 10.5% from 2025 to 2030. The growth of the preimplantation genetic testing market is driven by the decline in global fertility rates and clinician guidance encouraging euploid single-embryo transfer (SET), among other factors.

KEY TAKEAWAYS

  • BY PROCEDURE TYPE
    The procedure type segment comprises preimplantation genetic screening and preimplantation genetic diagnosis. Preimplantation genetic screening is highly demanded with the rising demand for assisted reproductive technologies.
  • BY TECHNOLOGY
    Key technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH). NGS dominates the market with increasing use of these systems in fertility clinics and research institutes for preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD).
  • BY APPLICATION
    The key application of preimplantation genetic testing is aneuploidy. Increasing maternal age and the rising prevalence of aneuploidy are factors supporting growth.
  • BY REGION
    The preimplantation genetic testing market covers North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America is the largest market for preimplantation genetic testing, mainly owing to the rising awareness of preimplantation genetic testing procedures.
  • COMPETITIVE LANDSCAPE
    Major market players have adopted organic and inorganic strategies, including product launches, partnerships, and investments. For instance, in July 2023, Thermo Fisher Scientific Inc. (US) launched two new NGS-based test kits to support preimplantation genetic testing for aneuploidy (PGT-A), commonly used in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.

The preimplantation genetic testing (PGT) market is witnessing steady growth, driven by the factors such as drop in the fertility rates globally, along with growing focus on euploid single-embryo transfer (SET). Non-invasive PGT and AI-enhanced embryo selection and PGT bundling are some of the key opportunity areas in this market.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact on the preimplantation genetic testing (PGT) market is shaped by evolving patient needs, advances in genetic technology, and regulatory dynamics. IVF clinics, fertility centers, diagnostic laboratories, and genetic counseling services are the main adopters of PGT, with embryo selection and genetic disease prevention as core objectives. Adoption of new testing methodologies, increasing demand for personalized reproductive medicine, and stricter compliance requirements are directly influencing workflows and clinical outcomes for end users.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Decline in global fertility rates
  • Clinician guidance encouraging euploid single-embryo transfer (SET)
RESTRAINTS
Impact
Level
  • High cost and reimbursement hurdles
OPPORTUNITIES
Impact
Level
  • Non-invasive PGT
  • AI-enhanced embryo selection and PGT bundling
CHALLENGES
Impact
Level
  • Socio-ethical concerns around PGT

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Decline in global fertility rates.

The sustained decline in global fertility, driven by delayed childbearing, urban lifestyles, and socioeconomic pressures, is pushing more couples toward assisted reproduction. As average maternal age rises, so does the risk of aneuploidy and inherited disorders, increasing the clinical utility of PGT to identify euploid or unaffected embryos. Fertility clinics and IVF labs are therefore integrating PGT earlier in care pathways to improve success per transfer and reduce time-to-pregnancy.

Restraint: High cost and reimbursement hurdles

High out-of-pocket costs for IVF plus add-on PGT (biopsy, sequencing, logistics, and counseling) remain a major barrier to adoption, especially in cash-pay markets. Coverage is inconsistent; many plans exclude PGT-A or limit reimbursement to clear medical indications like PGT-M/PGT-SR, creating uncertainty for patients and clinics. This leads to deferral of testing, lower attach rates, and fragmented uptake concentrated in higher-income segments or employer-sponsored benefit cohorts. Until broader reimbursement and transparent bundle pricing mature, cost sensitivity is expected to limit penetration outside top-tier urban centers and cross-border hubs.

Opportunity: Non-invasive PGT

Non-invasive PGT (niPGT) analyzes cell-free embryonic DNA from spent culture media, potentially eliminating the risks associated with trophectoderm biopsy and simplifying the workflow. By reducing procedural complexity and perceived harm, niPGT can widen testing to cost- and risk-averse patients and earlier-stage clinics. Lower consumables and staffing needs create room for bundled pricing and higher attach rates per IVF cycle. Integration with time-lapse imaging and AI scoring can deliver a “screen-and-select” pathway, improving throughput and counseling. As multi-center validation tightens accuracy and regulators clarify requirements, niPGT is positioned to unlock new demand in both premium and value segments.

Challenge: Socio-ethical concerns around PGT

Socio-ethical debates around embryo selection, spanning concerns of eugenics, disability rights, sex selection, and equitable access, create reputational and policy risks for providers. Varying cultural and religious views drive inconsistent regulations and limit public acceptance, especially for PGT-A in non-medical contexts. Informed-consent complexity, data privacy for genomic results, and counseling burdens add operational friction. Media scrutiny and litigation risk can deter clinics from promoting their services broadly and payers from providing coverage. These factors slow guideline harmonization and keep adoption uneven across regions, even when clinical utility is demonstrated.

MARKET ECOSYSTEM

The preimplantation genetic testing (PGT) market ecosystem involves a network of key players, including reagent and assay suppliers (such as Illumina, Thermo Fisher Scientific), instrument and software solution providers (Agilent Technologies, Revvity, Qiagen), and end users like fertility clinics and specialized IVF centers. Reagents and instruments enable advanced genetic analysis and embryo screening, while digital tools streamline data interpretation and reporting. Fertility clinics and IVF centers apply these technologies to select healthy embryos, meet patient demand for successful outcomes, and minimize genetic risks.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Preimplantation Genetic Testing Market, By Procedure Type

Preimplantation genetic screening holds the largest share of the market. A decline in female fertility linked to increased maternal age, along with a higher incidence of genetic disorders in children, is fueling the demand for preimplantation genetic testing. This approach offers diverse advantages, such as greater chances of healthy pregnancies regardless of age, improved implantation success, and a lower likelihood of miscarriage.

Preimplantation Genetic Testing Market, By Type of cycle

In 2024, fresh non-donor dominated the market based on the type of cycle. The substantial share of this market segment can be attributed to factors like higher success rates, streamlined implantation procedures, and increased efficiency in embryo generation. This segment shows higher implantation success rates and better embryo viability. Additionally, using fresh embryos from non-donor cycles is closely aligned with standard IVF protocols, contributing to greater utilization and a larger market share in this segment.

Preimplantation Genetic Testing Market, By End user

In 2024, fertility clinics dominated the market. This is mainly due to the growing global network of fertility centers and clinics, which has made advanced reproductive technologies more accessible to patients. Fertility clinics are recognized for providing high treatment success rates, which further encourages patients to choose these specialized facilities. Moreover, the rise of medical tourism, especially in emerging markets, has attracted international patients to fertility clinics that offer competitive pricing and high-quality care, thereby expanding the segment's market share.

REGION

Asia Pacific to be fastest-growing region in global Preimplantation Genetic Testing (PGT) market during forecast period

The Asia Pacific PGT market is expected to register the highest CAGR during the forecast period, driven by increasing public awareness about advanced infertility treatments. Additionally, countries in this region are emerging as popular destinations for medical tourism, with cost-effective and high-quality infertility care attracting an increasing number of international patients. As a result, the demand for innovative reproductive technologies and genetic testing procedures continues to increase across many Asia-Pacific countries.

Preimplantation Genetic Testing Market: COMPANY EVALUATION MATRIX

Within the preimplantation genetic testing market landscape, Illumina (Star) maintains a leadership position, backed by robust market share and an expansive portfolio of genomic solutions that have become standard in fertility centers globally. The company’s advanced sequencing platforms and diagnostic assays are widely adopted. Abbott (Emerging Leader) is increasing its footprint by with its preimplantation genetic testing FISH products.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 636.4 Million
Market Forecast in 2030 (Value) USD 1,135.0 Million
Growth Rate CAGR of 10.5% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Million)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Procedure type:
    • Preimplantation Genetic Screening
    • Preimplantation Genetic Diagnosis
  • By Technology:
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
    • Fluorescence In Situ Hybridization
    • Comparative Genomic Hybridization
    • Single-Nucleotide Polymorphism
  • By Product:
    • Reagents and Consumables
    • Instruments
    • Software
  • By Application:
    • Aneuploidy
    • Structural chromosomal abnormalities
    • Single gene disorders
    • X-linked disorders
    • HLA typing
    • Gender identification
  • By Type of cycle:
    • Fresh Non-Donor
    • Frozen Non-Donor
    • Fresh Donor
    • Frozen Donor
  • By End user:
    • Fertility clinics
    • Hospitals
    • Diagnostic laboratories
    • other end users
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa

WHAT IS IN IT FOR YOU: Preimplantation Genetic Testing Market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Diagnostic Company
  • Market landscape analysis for PGT adoption
  • Collaboration opportunity identification
  • Feasibility review for next-gen PGT technologies
  • Partnership opportunities
  • Inform strategic product launches
  • Support investment forecasting 
IVF Clinic
  • PGT solution vendor mapping
  • Workflow comparison across leading PGT platforms
  • Enable platform selection
  • Guide evidence-based patient counseling
  • Benchmark best practices

RECENT DEVELOPMENTS

  • September 2025 : In September 2025, Illumina’s market access team focused on expanding noninvasive prenatal testing (NIPT) and preimplantation genetic testing access in Abu Dhabi, UAE.
  • July 2023 : Thermo Fisher Scientific (US) launched two new NGS-based test kits to support preimplantation genetic testing aneuploidy (PGT-A), commonly used in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.
  • June 2023 : Oxford Gene Technology (UK) partenered with Applied Spectral Imaging (US). This commercial partnership will grant OGT rights to market ASI’s proprietary cytogenetic imaging and analysis solutions in the UK.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
22
RESEARCH METHODOLOGY
27
EXECUTIVE SUMMARY
40
PREMIUM INSIGHTS
47
MARKET OVERVIEW
51
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Decline in fertility rates
    - Rise of fertility tourism in emerging economies
    - Increasing number of fertility clinics and IVF centers
    - Increasing public-private investments to develop novel diagnostic techniques
    - High risk of chromosomal abnormalities with advancing maternal age
    RESTRAINTS
    - High procedural cost
    - Unfavorable government regulations and healthcare reforms for IVF procedures
    OPPORTUNITIES
    - Improving healthcare infrastructure and rising medical tourism in emerging economies
    - Use of fertility treatments by single parents and same-sex couples
    CHALLENGES
    - Socio-ethical concerns surrounding preimplantation genetic testing
    - Age-related procedural challenges
  • 5.3 PRICING ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 ECOSYSTEM MARKET MAP
  • 5.8 REGULATORY ANALYSIS
    NORTH AMERICA
    - US
    - Canada
    EUROPE
    - UK
    - France
    ASIA PACIFIC
    - Japan
    - India
  • 5.9 PATENT ANALYSIS
    PATENT TRENDS FOR PREIMPLANTATION GENETIC TESTING
    JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
    REVENUE SHIFT FOR PREIMPLANTATION GENETIC TESTING PRODUCTS
  • 5.11 KEY CONFERENCES AND EVENTS IN 2023–2024
  • 5.12 TECHNOLOGY ANALYSIS
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.14 TRADE ANALYSIS
PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE
75
  • 6.1 INTRODUCTION
  • 6.2 PREIMPLANTATION GENETIC SCREENING
    INCREASING MATERNAL AGE TO DRIVE MARKET
  • 6.3 PREIMPLANTATION GENETIC DIAGNOSIS
    RISING AWARENESS ABOUT CHROMOSOMAL ABNORMALITIES IN FETUSES TO DRIVE MARKET
PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY
79
  • 7.1 INTRODUCTION
  • 7.2 NEXT-GENERATION SEQUENCING
    IMPROVED TECHNOLOGY FOR DETECTING STRUCTURAL ABNORMALITIES TO DRIVE MARKET
  • 7.3 POLYMERASE CHAIN REACTION
    INCREASED USAGE IN CLINICAL AND RESEARCH APPLICATIONS AND HIGH PREVALENCE OF GENETIC DISEASES TO DRIVE MARKET
  • 7.4 FLUORESCENCE IN SITU HYBRIDIZATION
    ADVANCES IN FLUORESCENCE MICROSCOPY AND DIGITAL IMAGING TO DRIVE MARKET
  • 7.5 COMPARATIVE GENOMIC HYBRIDIZATION
    LOW COST, LESS LABOR REQUIREMENT, AND ONGOING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
  • 7.6 SINGLE-NUCLEOTIDE POLYMORPHISM
    TIME-CONSUMING, EXPENSIVE, AND LABOR-INTENSIVE METHOD TO LIMIT MARKET
PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE
86
  • 8.1 INTRODUCTION
  • 8.2 REAGENTS AND CONSUMABLES
    REAGENTS AND CONSUMABLES SEGMENT TO DOMINATE PREIMPLANTATION GENETIC TESTING MARKET
  • 8.3 INSTRUMENTS
    ONGOING TECHNOLOGICAL ADVANCEMENTS AND INCREASING FERTILITY CLINICS TO DRIVE MARKET
  • 8.4 SOFTWARE AND SERVICES
    RISING AWARENESS ABOUT DATA ANALYSIS TO DRIVE MARKET
PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION
91
  • 9.1 INTRODUCTION
  • 9.2 ANEUPLOIDY
    ANEUPLOIDY SEGMENT TO COMMAND LARGEST MARKET SHARE
  • 9.3 STRUCTURAL CHROMOSOMAL ABNORMALITIES
    TRANSLOCATIONS
    - Rising incidence of translocation chromosomal abnormalities during IVF treatments to drive segment
    DELETIONS
    - Advancements in genetic testing to drive segment
    DUPLICATIONS
    - Rising cases of duplication of chromosomal abnormalities and increasing maternal age to drive segment
    INVERSIONS
    - Risk of unexplained male-factor infertility and multiple miscarriages to limit segment
  • 9.4 SINGLE GENE DISORDERS
    INCREASING AWARENESS ABOUT GENETIC TESTING TO DRIVE MARKET
  • 9.5 X-LINKED DISORDERS
    MEDICAL ADVANCEMENTS AND INCREASED RESEARCH ON GENETIC DISORDERS TO DRIVE MARKET
  • 9.6 HLA TYPING
    RISING NUMBER OF COUPLES WITH CHILDREN AFFECTED BY HEMATOLOGICAL DISEASES TO DRIVE MARKET
  • 9.7 GENDER IDENTIFICATION
    INCREASED FOCUS ON SEX DISCRIMINATION TO LIMIT MARKET
PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE
103
  • 10.1 INTRODUCTION
  • 10.2 FRESH NON-DONOR
    HIGH RATES OF SUCCESSFUL PREGNANCY AMONG YOUNG WOMEN TO DRIVE MARKET
  • 10.3 FROZEN NON-DONOR
    LONG-TERM STORAGE OF FROZEN EGGS AND EASY SCHEDULING TO DRIVE MARKET
  • 10.4 FROZEN DONOR
    BETTER AFFORDABILITY, HIGHER AVAILABILITY, AND EASIER IMPLANTATION TO DRIVE MARKET
  • 10.5 FRESH DONOR
    REAL-TIME GENETIC TESTING RESULTS AND EASY EMBRYO TRANSFER TO DRIVE MARKET
PREIMPLANTATION GENETIC TESTING MARKET, BY END USER
109
  • 11.1 INTRODUCTION
  • 11.2 FERTILITY CLINICS
    HIGH SUCCESS RATE OF TREATMENT TO DRIVE MARKET
  • 11.3 HOSPITALS
    RISING NUMBER OF HOSPITALS FOR ART PROCEDURES TO DRIVE MARKET
  • 11.4 DIAGNOSTIC LABORATORIES
    IMPROVED CLINICAL EFFICACY AND INCREASED RESEARCH FUNDING TO DRIVE MARKET
  • 11.5 OTHER END USERS
PREIMPLANTATION GENETIC TESTING MARKET, BY REGION
115
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - US to dominate North American preimplantation genetic testing market during forecast period
    CANADA
    - Increasing government and non-government funding for curbing rising infertility rates to drive market
  • 12.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Low fertility rate and low cost of infertility treatment to drive market
    FRANCE
    - Rising government funding for genomics research and increasing median age for first-time pregnancies to drive market
    UK
    - Increasing IVF cycles and growing genetic abnormalities to drive market
    ITALY
    - Technological advancements in fertility treatment and decline in fertility rates among women to drive market
    SPAIN
    - Low cost of fertility treatment to drive market
    REST OF EUROPE
  • 12.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    CHINA
    - Decreasing fertility rates and abolishment of one-child policy to drive market
    JAPAN
    - Rising adoption of IVF among infertile couples to drive market
    INDIA
    - Rising medical tourism and increasing fertility clinics to drive market
    REST OF ASIA PACIFIC
  • 12.5 REST OF THE WORLD
    LATIN AMERICA: RECESSION IMPACT
    MIDDLE EAST & AFRICA: RECESSION IMPACT
COMPETITIVE LANDSCAPE
186
  • 13.1 OVERVIEW
  • 13.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
  • 13.3 REVENUE ANALYSIS OF KEY PLAYERS
  • 13.4 MARKET SHARE ANALYSIS
  • 13.5 COMPANY EVALUATION MATRIX OF KEY PLAYERS
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
  • 13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES
    PROGRESSIVE COMPANIES
    STARTING BLOCKS
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
  • 13.7 COMPANY FOOTPRINT ANALYSIS
  • 13.8 COMPETITIVE BENCHMARKING
  • 13.9 COMPETITIVE SCENARIOS AND TRENDS
    KEY PRODUCT LAUNCHES AND APPROVALS
    KEY DEALS
    OTHER KEY DEVELOPMENTS
COMPANY PROFILES
198
  • 14.1 KEY PLAYERS
    ILLUMINA, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products/Services offered
    - MnM view
    REVVITY
    - Business overview
    - Products/Services offered
    - Recent developments
    THE COOPER COMPANIES, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    ABBOTT
    - Business overview
    - Products/Services offered
    TAKARA BIO INC.
    - Business overview
    - Products/Services offered
    QIAGEN
    - Business overview
    - Products/Services offered
    VITROLIFE
    - Business overview
    - Products/Services offered
    - Recent developments
    OXFORD NANOPORE TECHNOLOGIES PLC
    - Business overview
    - Products/Services offered
  • 14.2 OTHER PLAYERS
    OXFORD GENE TECHNOLOGY IP LIMITED
    - Recent developments
    YIKON GENOMICS
    SHIVA SCIENTIFIC COMPANY
    NANJING SUPERYEARS GENE TECHNOLOGY CO., LTD.
    MEDICOVER GENETICS
    MEDGENOME
    FULGENT GENETICS
    INVICTA GENETICS
    GENEA LIMITED
    SCIEGENE CORPORATION
    BIOARRAY S.L.
    UNIMED BIOTECH (SHANGHAI) CO., LTD.
    GENEMIND BIOSCIENCES CO., LTD.
    BERRY GENOMICS
    BANGKOK GENOMICS INNOVATION
APPENDIX
229
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 RISK ASSESSMENT: PREIMPLANTATION GENETIC TESTING MARKET
  • TABLE 2 FERTILITY RATE, TOTAL (BIRTHS PER WOMAN), BY COUNTRY
  • TABLE 3 GLOBAL INCIDENCE RATE OF TRISOMY
  • TABLE 4 INDICATIVE PRICING OF PREIMPLANTATION GENETIC TESTING PRODUCTS
  • TABLE 5 AVERAGE SELLING PRICE OF PREIMPLANTATION GENETIC TESTING SYSTEMS
  • TABLE 6 ROLE IN ECOSYSTEM: PREIMPLANTATION GENETIC TESTING MARKET
  • TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING PREIMPLANTATION GENETIC TESTING MARKET
  • TABLE 8 DETAILED LIST OF CONFERENCES AND EVENTS (JANUARY 2023–DECEMBER 2024)
  • TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PREIMPLANTATION GENETIC TESTING PRODUCTS (%)
  • TABLE 10 KEY BUYING CRITERIA FOR END USERS OF PREIMPLANTATION GENETIC TESTING PRODUCTS
  • TABLE 11 IMPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 12 EXPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 13 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 14 PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC SCREENING, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 15 PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 16 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 17 PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 18 PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 19 PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 20 PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 21 PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 22 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 23 PREIMPLANTATION GENETIC TESTING MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 24 PREIMPLANTATION GENETIC TESTING MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 25 PREIMPLANTATION GENETIC TESTING MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 26 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 27 PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 28 PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 29 PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 30 TRANSLOCATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 31 DELETIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 32 DUPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 33 INVERSIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 34 PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 35 PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 36 PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 37 PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 38 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 39 PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONORS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 40 PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 41 PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 42 PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 43 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 44 PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 45 PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 46 PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 47 PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 48 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 49 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 50 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 51 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 52 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 53 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 54 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 55 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 56 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 57 US: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 58 US: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 59 US: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 60 US: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 61 US: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 62 US: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 63 US: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 64 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 65 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 66 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 67 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 68 CANADA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 69 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 70 CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 71 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 72 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 73 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 74 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 75 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 76 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 77 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 78 EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 79 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 80 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 81 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 82 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 83 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 84 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 85 GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 86 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 87 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 88 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 89 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 90 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 91 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 92 FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 93 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 94 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 95 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 96 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 97 UK: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 98 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 99 UK: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 100 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 101 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 102 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 103 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 104 ITALY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 105 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 106 ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 107 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 108 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 109 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 110 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 111 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 112 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 113 SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 114 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 115 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 116 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 117 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 118 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 119 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 120 REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 129 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 130 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 131 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 132 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 133 CHINA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 134 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 135 CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 136 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 137 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 138 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 139 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 140 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 141 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 142 JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 143 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 144 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 145 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 146 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 147 INDIA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 148 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 149 INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 150 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 151 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 152 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 153 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 154 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 155 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 156 REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 157 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2021–2028 (USD MILLION)
  • TABLE 158 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 159 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2021–2028 (USD MILLION)
  • TABLE 160 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 161 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 162 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2021–2028 (USD MILLION)
  • TABLE 163 REST OF THE WORLD: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 164 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET
  • TABLE 165 DEGREE OF COMPETITION: PREIMPLANTATION GENETIC TESTING MARKET
  • TABLE 166 OVERALL FOOTPRINT
  • TABLE 167 PRODUCT FOOTPRINT
  • TABLE 168 REGIONAL FOOTPRINT
  • TABLE 169 DETAILED LIST OF KEY START-UPS/SMES IN PREIMPLANTATION GENETIC TESTING MARKET
  • TABLE 170 KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023
  • TABLE 171 KEY DEALS, 2020–2023
  • TABLE 172 OTHER KEY DEVELOPMENTS, 2020–2023
  • TABLE 173 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 174 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 175 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 176 REVVITY: COMPANY OVERVIEW
  • TABLE 177 THE COOPER COMPANIES, INC.: COMPANY OVERVIEW
  • TABLE 178 ABBOTT: COMPANY OVERVIEW
  • TABLE 179 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 180 QIAGEN.: COMPANY OVERVIEW
  • TABLE 181 VITROLIFE.: COMPANY OVERVIEW
  • TABLE 182 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN: PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 6 MARKET SIZE ESTIMATION, BY PRODUCT UTILIZATION METHODOLOGY
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 TOP-DOWN APPROACH
  • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 11 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
  • FIGURE 12 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 13 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
  • FIGURE 14 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 15 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
  • FIGURE 16 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
  • FIGURE 17 RISING MATERNAL AGE AND DECLINING FERTILITY RATES TO DRIVE MARKET
  • FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 19 US AND REAGENTS AND CONSUMABLES SEGMENT COMMANDED LARGEST MARKET SHARE IN 2022
  • FIGURE 20 ASIA PACIFIC COUNTRIES TO GROW AT HIGHEST RATE DURING STUDY PERIOD
  • FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • FIGURE 23 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY OF PROMINENT COMPANIES
  • FIGURE 24 ECOSYSTEM MARKET MAP: PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 25 KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 26 PATENT TRENDS FOR PREIMPLANTATION GENETIC TESTING, JANUARY 2013–AUGUST 2023
  • FIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PREIMPLANTATION GENETIC TESTING PATENTS, JANUARY 2013–AUGUST 2023
  • FIGURE 28 REVENUE SHIFT FOR PREIMPLANTATION GENETIC TESTING PRODUCTS
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PREIMPLANTATION GENETIC TESTING PRODUCTS
  • FIGURE 30 KEY BUYING CRITERIA FOR END USERS OF PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 31 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT
  • FIGURE 32 ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT
  • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
  • FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UPS/SMES
  • FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 39 REVVITY: COMPANY SNAPSHOT (2022)
  • FIGURE 40 THE COOPER COMPANIES INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2022)
  • FIGURE 42 TAKARA BIO INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2022)
  • FIGURE 44 VITROLIFE: COMPANY SNAPSHOT (2022)

Methodology

This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

Secondary Research

Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

Preimplantation Genetic Testing Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

Preimplantation Genetic Testing Market

Data Triangulation

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

Market Definition

Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

  • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
  • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
  • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

Stakeholders

  • Contract research organizations (CROs)
  • Contract development and manufacturing organizations (CDMOs)
  • In vitro fertilization (IVF) centers and fertility clinics
  • Life science companies
  • Fertility clinics
  • Academic & research institutes
  • Private research institutes
  • Venture capitalists & investors
  • Market research & consulting firms
  • Government associations
  • Medical institutions & universities
  • Hospitals & clinics

Report Objectives

  • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
  • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
  • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Preimplantation Genetic Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Preimplantation Genetic Testing Market

DMCA.com Protection Status